3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
3
Other hematologic neoplasm
2
Myeloid
1
Conditions
Thrombocytopenia
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Interventions
eltrombopag
3
Platelet Transfusion
2
Busulfan
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
siltuximab
1
oprelvekin
1
fludarabine phosphate
1
fludarabine
1
Vitamin E
1
Tranexamic Acid
1
Topotecan
1
Stem Cell Transplantation
1
Peripheral Blood Stem Cell Transplantation
1
Observation
1
Microarray Analysis
1
Isotretinoin
1
Interleukin-11
1
Hematopoietic Stem Cell Transplantation
1
Gene Expression Profiling
1
Flow Cytometry
1
Filgrastim
1
Etoposide
1
Decitabine
1
DNA Methylation
1
Cytogenetic Analysis
1
Cytarabine
1
Cyclophosphamide
1
Biopsy
1
Amplified Fragment Length Polymorphism Analysis
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thrombocytopenia
×
Tranexamic Acid
×
Myeloid
×
Clear all
NCT06599762
2026-04-22
MYELO-CAN:TXA
University of Manitoba
Phase 2
Recruiting
75 enrolled